Alnylam presents positive results from the kardia-1 phase 2 dose-ranging study of zilebesiran, an investigational rnai therapeutic in development for the treatment of hypertension in patients at high cardiovascular risk

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced positive results from the kardia-1 phase 2 study of zilebesiran, an investigational rnai therapeutic targeting liver-expressed angiotensinogen (agt) in development for the treatment of patients with hypertension and high cardiovascular risk. the study results were presented during the american heart association (aha) scientific sessions being held in philadelph.
ALNY Ratings Summary
ALNY Quant Ranking